Literature DB >> 1881437

Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs.

G Acsadi1, G Dickson, D R Love, A Jani, F S Walsh, A Gurusinghe, J A Wolff, K E Davies.   

Abstract

Duchenne's muscular dystrophy (DMD), which affects one in 3,500 males, causes progressive myopathy of skeletal and cardiac muscles and premature death. One approach to treatment would be to introduce the normal dystrophin gene into diseased muscle cells. When pure plasmid DNA is injected into rodent skeletal or cardiac muscle, the cells express reporter genes. We now show that a 12-kilobase full-length human dystrophin complementary DNA gene and a 6.3-kilobase Becker-like gene can be expressed in cultured cells and in vivo. When the human dystrophin expression plasmids are injected intramuscularly into dystrophin-deficient mdx mice, the human dystrophin proteins are present in the cytoplasm and sarcolemma of approximately 1% of the myofibres. Myofibres expressing human dystrophin contain an increased proportion of peripheral nuclei. The results indicate that transfer of the dystrophin gene into the myofibres of DMD patients could be beneficial, but a larger number of genetically modified myofibres will be necessary for clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1881437     DOI: 10.1038/352815a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  71 in total

1.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.

Authors:  B Wang; J Li; X Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Transferring myoblasts in Duchenne dystrophy.

Authors:  V Dubowitz
Journal:  BMJ       Date:  1992-10-10

Review 3.  Recent advances in understanding muscular dystrophy.

Authors:  K M Bushby
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

4.  Aerosol gene delivery in vivo.

Authors:  R Stribling; E Brunette; D Liggitt; K Gaensler; R Debs
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

5.  Signs of progress in gene therapy for muscular dystrophy also warrant caution.

Authors:  Hansell H Stedman; Barry J Byrne
Journal:  Mol Ther       Date:  2012-02       Impact factor: 11.454

6.  An intact cysteine-rich domain is required for dystrophin function.

Authors:  R D Bies; C T Caskey; R Fenwick
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

7.  Widespread long-term gene transfer to mouse skeletal muscles and heart.

Authors:  L D Stratford-Perricaudet; I Makeh; M Perricaudet; P Briand
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

8.  Stability and functional effectiveness of phosphorothioate modified duplex DNA and synthetic 'mini-genes'.

Authors:  S A Ciafrè; M Rinaldi; P Gasparini; D Seripa; L Bisceglia; L Zelante; M G Farace; V M Fazio
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

9.  Gene inoculation generates immune responses against human immunodeficiency virus type 1.

Authors:  B Wang; K E Ugen; V Srikantan; M G Agadjanyan; K Dang; Y Refaeli; A I Sato; J Boyer; W V Williams; D B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

10.  Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle.

Authors:  C O Harding; K Wild; D Chang; A Messing; J A Wolff
Journal:  Gene Ther       Date:  1998-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.